The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?

November 19, 2015

The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study sought to determine the effects of empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for CVD. Does the evidence from the EMPA-REG OUTCOME study coupled with the other benefits of SGLT2 inhibitors (reduction in weight and blood pressure, mild adverse effects) make empagliflozin the preferred second-line agent from the treatment of type 2 diabetes? 

00:0000:00

Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?

July 10, 2015

The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM.  The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.

00:0000:00